Germline Mutations in FAF1 Are Associated With Hereditary Colorectal Cancer by Bonjoch Gassol, Laia et al.
Gastroenterology 2020;159:227–240Germline Mutations in FAF1 Are Associated With Hereditary
Colorectal Cancer
Laia Bonjoch,1 Sebastià Franch-Expósito,1 Pilar Garre,2 Sami Belhadj,3 Jenifer Muñoz,1
Coral Arnau-Collell,1 Marcos Díaz-Gay,1 Anna Gratacós-Mulleras,1 Giulia Raimondi,4
Clara Esteban-Jurado,1 Yasmin Soares de Lima,1 Cristina Herrera-Pariente,1
Miriam Cuatrecasas,5 Teresa Ocaña,1 Antoni Castells,1 Cristina Fillat,4 Gabriel Capellá,3
Francesc Balaguer,1 Trinidad Caldés,2 Laura Valle,3 and Sergi Castellví-Bel1
1Gastroenterology Department, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigación
Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Hospital Clínic, Universitat de Barcelona, Barcelona,
Spain; 2Molecular Oncology Laboratory, Centro Investigación Biomédica en Red de Cáncer (CIBERONC). Hospital Clínico San
Carlos. Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain; 3Hereditary Cancer Program, Catalan Institute of
Oncology, Oncobell, Institut d’Investigació Biomèdica de Bellvitge (IDIBELL), Centro de Investigación Biomédica en Red de Cáncer
(CIBERONC), Barcelona, Spain; 4Gene Therapy and Cancer, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS),
Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Universitat de Barcelona, Barcelona, Spain; and
5Pathology Department, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigación Biomédica en



































to CRCBACKGROUND & AIMS: A significant proportion of colorectal
cancer (CRC) cases have familial aggregation but little is known
about the genetic factors that contribute to these cases. We per-
formed an exhaustive functional characterization of genetic vari-
ants associated with familial CRC. METHODS: We performed
whole-exome sequencing analyses of 75 patients from 40 families
with a history of CRC (including early-onset cases) of an unknown
germline basis (discovery cohort). We also sequenced specific
genes in DNA from an external replication cohort of 473 families,
including 488 patients with colorectal tumors that had normal
expression of mismatch repair proteins (validation cohort). We
disrupted the Fas-associated factor 1 gene (FAF1) in DLD-1 CRC
cells using CRISPR/Cas9 gene editing; some cells were transfected
with plasmids that express FAF1 missense variants. Cells were
analyzed by immunoblots, quantitative real-time polymerase chain
reaction, and functional assays monitoring apoptosis, proliferation,
and assays for Wnt signaling or nuclear factor (NF)-kappa-Bactivity. RESULTS: We identified predicted pathogenic variant in
the FAF1 gene (c.1111G>A; p.Asp371Asn) in the discovery cohort;
it was present in 4 patients of the same family. We identified a
second variant in FAF1 in the validation cohort (c.254G>C;
p.Arg85Pro). Both variants encoded unstable FAF1 proteins.
Expression of these variants in CRC cells caused them to become
resistant to apoptosis, accumulate beta-catenin in the cytoplasm,
and translocate NF-kappa-B to the nucleus. CONCLUSIONS: In
whole-exome sequencing analyses of patients from families with a
history of CRC, we identified variants in FAF1 that associate with
development of CRC. These variants encode unstable forms of
FAF1 that increase resistance of CRC cells to apoptosis and in-
crease activity of beta-catenin and NF-kappa-B.Keywords: Wnt Signaling; Programmed Cell Death; Gene Edit-
ing; Functional Genomics.
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ATolorectal cancer (CRC) is one of the most frequentBACKGROUND AND CONTEXT
Next-generation sequencing is frequently used to identify
genetic variants associated with familial colorectal cancer
(CRC). Studies are then needed to analyze the functional
effects of these variants.
NEW FINDINGS
Using next-generation sequencing, the authors identified
variants in FAF1 carried by members of 2 families with
histories of CRC and early-onset CRC. CRC cells with
disruption of FAF1, or that overexpressed the variants
identified in the cohorts, became resistant to apoptosis
and had increased cytosolic beta-catenin and nuclear
NF-kappa-B.
LIMITATIONS
Additional studies, of larger cohorts, are needed to
determine how FAF1 variants contribute to hereditary
CRC. Studies of colon organoids are needed to
determine how these variants affect colon tissues.
IMPACT
The combination of next-generation sequencing and
functional analysis of identified disease-associated
variants is an effective strategy to identify mechanisms
of pathogenesis. It might be used to identify specific
mechanisms of disease development in individual
patients or families.
Abbreviations used in this paper: CETSA, cellular thermal shift assay;
CRC, colorectal cancer; DEDID, death effector domain-interacting
domain; FAF1, Fas-associated factor 1; FID, Fas-interacting domain;Cneoplasms worldwide, accounting for approxi-
mately 8% of all cancer-related deaths.1 A familial compo-
nent, defined by the presence of 2 or more affected relatives,
is estimated to be involved in 12% to 35% of all CRC
cases.2,3 However, only 5.2% of all CRC cases are caused by
known high-penetrance CRC genes (APC, MUTYH, the DNA
polymerases POLE and POLD1, and the mismatch repair
genes MLH1, MSH2, MSH6, and PMS2).4 Despite these he-
reditary syndromic forms, a large proportion of patients
with CRC have a family history of the disease but the un-
derlying germline cause remains unexplained. Part of this
familial risk could be related to uncommon and highly
penetrant mutations in genes yet to be discovered.
Numerous genes involved in CRC and/or polyposis predis-
position have been proposed, although, so far, strong evi-
dence of association has only been demonstrated for NTHL1,
MSH3, GREM1, RNF43, RSP20, and MLH3.5–8
In the past years, genome-wide next-generation
sequencing and copy-number technologies have been
widely used for the identification of new germline variants
involved in cancer predisposition. Nevertheless, recognizing
the correct causal pathogenic variant among the large
number of variants identified by using these genome-wide
techniques is not straightforward. The functional charac-
terization of the identified variants is a helpful approach to
establish the link to disease predisposition. To standardize
and facilitate this approach, key guidelines9,10 and experi-
mental scanning pipelines11,12 have been developed to
assess the functional relevance of the genetic variants. On
the other hand, CRISPR/Cas gene editing has transformed
functional genomics, enabling researchers to potentially edit
any desired region of the genome. Modeling by CRISPR/Cas
has allowed the characterization of several known heredi-
tary CRC genes (eg, MLH1 and POLE), as well as somatic CRC
mutational events (KRAS, TP53, SMAD4, and APC).13,14 Un-
doubtedly, the integration of next-generation sequencing
results with these models can help monitor the genomic
changes that trigger CRC development and allow more
personalized therapy designs. Nevertheless, these cancer
modeling tools have been scarcely used to decipher the
pathogenicity of many variants of uncertain significance.
In this study, we aimed at identifying novel causal genes
for CRC germline predisposition by performing whole-
exome sequencing in CRC families with an unknown germ-
line basis. The detected rare variants were functionally
evaluated to demonstrate their pathogenicity and implica-
tions in predisposing to CRC, permitting a more accurate
and adequate diagnosis of patients, as well as facilitating
genetic counseling and prevention.LOH, loss of heterozygosis; NF-kappa-B, nuclear factor-kappa-B; PCR,
polymerase chain reaction; pNA, p-nitroanilide; SNP, single nucleotide
polymorphism; sgRNA, single guide RNA; TNF, tumor necrosis factor;
TRAIL, TNF-related apoptosis-inducing ligand; UAS, ubiquitin-related
domain.
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We selected 75 patients from 40 families with strong CRC
aggregation where other known hereditary cancer syndromes
had been ruled out (unaffiliated) and compatible with an
autosomal dominant pattern of inheritance. The selectioncriteria were as follows: 3 or more relatives with CRC, 2 or
more consecutive affected generations, and at least 1 CRC
diagnosed before the age of 60. The presence of germline al-
terations in well-known genes related to hereditary CRC syn-
dromes (APC, MUTYH, and the DNA MMR genes) had been
previously ruled out for all probands. The tumors developed by
the probands were microsatellite stable, negative for MLH1
promoter methylation, and showed normal expression of the
MMR proteins MLH1, MSH2, MSH6, and PMS2. The entire
cohort was previously described in detail.15–17
For replication purposes, an independent hereditary non-
polyposis CRC cohort was available, and comprised 473 fam-
ilies including 488 MMR-proficient cancer affected patients,
96% of them affected with CRC. The mean age at cancer diag-
nosis was 49 (range: 16–82). Among the 473 studied families,
58 (12.2%) fulfilled the Amsterdam criteria, 385 (81.4%) the
Bethesda guidelines, and the remaining 30 (6.3%) none of the













ATestablished criteria for hereditary nonpolyposis CRC. Detailed
description of the cohort may be found in Belhadj et al.18
This study was approved by the institutional ethics com-
mittee (IDIBAPS: 2011/6440; IDIBELL: PR247/15) and written
informed consent was obtained in all cases.
For details on exome sequencing and variant prioritization
in initial cohort, mutation identification in pooled samples in
replication cohort, variant validation, segregation analysis, and
tumor loss of heterozygosis (LOH), as well as additional path-
ogenicity prediction tools, see the Supplementary Material.
Immunohistochemistry
Immunostains were performed on histological 2-mm sec-
tions from colon tumor and normal mucosa from patient III-5 of
family FAM13. More detailed information is provided in the
Supplementary Material.
Functional Characterization of Genetic Variants
Cell lines. The DLD-1 human CRC cell line was purchased
from the American Type Culture Collection (ATCC, Manassas,
VA) and cultured in RPMI-1640 medium supplemented with
10% fetal bovine serum (Gibco, Waltham, MA), at 37C in 5%
CO2.
Plasmids. LentiCRISPRv2-Puro (#98290; Addgene, Cam-
bridge, MA) and pcDNA3-beta-catenin vectors were available.
FAF1 ORF (NM_007051) cloned into pcDNA3.1þC-(K)-DYK
expression vector (OHu13027D, FLAG-tagged) was purchased
from GenScript (Nanjing, China).
Antibodies. Monoclonal antibody against FAF1
(ab183045) was from Abcam (Cambridge, UK). THE
DYKDDDDK antibody (A00187) was from GenScript. Anti-p65
(D14E12), anti-GAPDH (14C10), and anti-beta-catenin
(D10A8) were purchased from Cell Signaling (Danvers, MA).
Anti-PCNA (sc 9857-R) was from Santa Cruz Biotechnology
(Dallas, TX). Goat anti-rabbit (SA5-10036) and anti-mouse
(SA5-10176) DyLight 800 secondary antibodies were pur-
chased from Thermo Fisher Scientific (Waltham, MA).
CRISPR/Cas9-mediated FAF1 knockout
generation. The Benchling (http://benchling.com) and the
MIT (http://crispr.mit.edu) CRISPR tools were used to design
the single guide RNA (sgRNA) against the coding region of the
FAF1 gene. The sgRNA was cloned into the LentiCRISPRv2-Puro
vector and transiently transfected into the DLD-1 CRC cell line.
Two days later, transfected cells were puromycin-selected (4
mg/mL) and seeded into 96-well plates at a density of 1 cell/
well. After 3 weeks, several clones were characterized and
selected for further analysis. FAF1 editing was validated by
Sanger sequencing, and gene inactivation was checked by
quantitative real-time polymerase chain reaction (PCR) and
Western blot. The detailed protocol is included in the
Supplementary Material.
Site-directed mutagenesis. The Q5 Site-Directed
Mutagenesis Kit (NEB, Ipswich, MA) was used to introduce
missense variants in the wild-type pcDNA3.1-FAF1-DYK
expression vector, according to the manufacturer’s instructions.
Mutagenic primers were designed using the NEBaseChanger
tool and obtained from IDT (Coralville, IA). Mutagenesis prod-
ucts were verified by Sanger sequencing. Primer details are in
the Supplementary Table 4.
Protein extraction and Western blot. To obtain
whole-cell protein extracts, cells were lysed with RIPA buffer.To assess nuclear factor (NF)-kappa-B translocation and beta-
catenin accumulation, cytoplasmic and nuclear protein frac-
tions were separated by hypotonic lysis. Equal amounts of
protein lysates were resolved in NuPAGE Bis-Tris protein gel
electrophoresis and transferred onto PVDF membranes (Milli-
pore, Bedford, MA), according to manufacturer’s protocols
(Thermo Fisher). Proteins were blotted with the indicated
primary and secondary Dylight antibodies and detected by
using the Odyssey Imaging System (LI-COR, Lincoln, NE). The
detailed protocol is included in the Supplementary Material.
RNA extraction and quantitative real-time
PCR. Total RNA extraction was performed with the RNeasy
Mini Kit according to manufacturer’s instructions (Qiagen,
Hilden, Germany). RNA retrotranscription and PCR amplifica-
tion details are included in the Supplementary Material.
Functional assays. DLD-1 knockout clones for FAF1
were transiently transfected with wild-type (pWT) or mutated
(pArg85Pro, pAsp371Asn) plasmids using X-tremeGENE HP
DNA transfection reagent. Two days later, cells were subjected
to selection with 1000 mg/mL of G418 (InvivoGen, San Diego,
CA) for 72 hours, as the FAF1 expression pcDNA3.1 vector
carries a neomycin resistance cassette. Neomycin-resistant cells
were allowed to recover in complete RPMI medium for 2
additional days before performing functional tests.
Cellular Thermal Shift Assay (CETSA)
Cells expressing wild-type or missense variants were har-
vested, washed with phosphate-buffered saline, and equally
distributed into PCR tubes. Cell suspensions were shortly
heated to 6 different temperatures (from 53C to 58C, ±1C, 3
minutes) and immediately snap-frozen in a dry ice/ethanol
bath. Subsequently, cells were lysed by 3 freeze-thaw cycles.
After heating, stable proteins remain soluble while unstable
proteins denature and precipitate, permitting their isolation by
high-speed centrifugation (16,000g, 20 minutes at 4C). Soluble
protein fractions were run on Western blots for the protein
melting curve analysis.
Apoptosis
A colorimetric caspase-3 activity assay was performed ac-
cording to the manufacturer’s instructions, with some modifi-
cations (Sigma Aldrich, St Louis, MO). Briefly, cells were
stimulated with 20 ng/mL of tumor necrosis factor (TNF)-
related apoptosis-inducing ligand (TRAIL) at the indicated time
points and lysed in 30 mL of lysis buffer. Protein concentrations
were determined by using the Pierce BCA Protein Assay Kit
(Thermo Fisher) and 50 mg of each protein extract was assayed
with the colorimetric caspase-3 substrate Ac-DEVD-pNA. The
release of the yellow chromophore p-nitroanilide (pNA) was
measured in an Epoch Microplate Spectrophotometer (BioTek,
Winooski, VT) at 405 nm. Caspase-3 activity was calculated in
comparison to a pNA standard curve.
Wnt Signaling
FAF1 wild-type (FAF1WT) and FAF1 knockout (FAF1KO) cells
were cotransfected with a pcDNA3-beta-catenin expression
vector together with the pcDNA3 control empty vector or one
of the FAF1 vectors (pWT, pArg85Pro, pAsp371Asn), as previ-
ously described. When indicated, after cell selection and re-
covery, cells were treated with the proteasome inhibitor




ATMG132 (10 mM) for 4 hours. Transfected cells were harvested
to extract the cytoplasmic protein fraction, and beta-catenin
was detected by Western blotting.
Cell proliferation, colony formation, and migration methods
are detailed in the Supplementary Material.Results
The variant prioritization strategy applied to whole-
exome sequencing data obtained from the initial unaffiliated
familial cohort (75 individuals from 40 families) selected a
FAF1 (Fas-associated factor 1) missense variant (c.1111G>A
p.Asp371Asn), predicted pathogenic by in silico algorithms.
The FAF1 variant was noticeable among others due to the
gene function as a mediator of apoptosis and a negative
regulator of both NF-kappa-B and Wnt signaling pathways.
The variant was identified in an Amsterdam-positive family of
Spanish origin with 5 CRC cases and 3 affected generations
(FAM13; Figure 1). The identified variant was initially
detected in 3 CRC-affected family members (ages at diagnosis
46–74) and in 1 relative diagnosedwith advanced adenoma atage 47 (Supplementary Figure 2A). An RAD52 truncation
variant, c.590_593dupAACC (p.Ser199Thrfs*88), was also
detected in the 3 CRC-affected family members but not in the
relative with the advanced adenoma.15 The 3 CRC-affected
members did not share additional genetic variants with a
plausible role in cancer predisposition. Targeted gene
sequencing of FAF1 in 473 additional genetically unexplained
CRC families yielded the identification of another predicted
pathogenic missense variant, c.254G>C (p.Arg85Pro). It was
identified in a Bethesda-positive patient with CRC diagnosed
at the age of 55 (F-0681-00; Figure 1 and Supplementary
Figure 2B). Additional samples for variant segregation and
tumor sample were not available.
The 2 identified missense variants are rare in large pop-
ulation datasets (ExAC database: allele count 5/121,210 for
p.Asp371Asn and 19/121,270 for p.Arg85Pro) and are pre-
dicted to be pathogenic by most in silico tools (eg, CADD: 36
for p.Asp371Asn and 23.4 for p.Arg85Pro). The p.Arg85Pro
variant is located on the FID domain (Fas-interacting
domain) of the protein, and the p.Asp371Asn variant affects
both the DEDID domain (death effector domain-interactingFigure 1. Pedigrees of
FAM13 and F-0681-00.
Filled symbol indicated
affected for CRC (upper
right quarter) adenoma/s
(lower right quarter), pros-
tate and pancreatic cancer
(lower left quarter). CRC,
lung, prostate, pancreas,
and gallbladder refer to the
type of cancer. Individual
IV-5 from FAM13 pre-
sented an advanced ade-
noma (tubulovillous, high-
grade dysplasia, 15 mm)
at the age of 47. Cose-




iants are also shown. AA/
non-AA, advanced
adenoma/non-advanced
adenoma. Ages at diag-
nosis are indicated. The
proband is indicated by an
arrow.
July 2020 FAF1 in Hereditary Colorectal Cancer 231domain) and an ubiquitin-related domain (UAS). The
p.Arg85Pro variant was predicted to alter the conformational
structure of FAF1 (DAMpred), whereas the p.Asp371Asn
amino acid change was predicted to impair the acetylation of
the nearby K368 residue (MutPred2).
Tumor material from 2 p.Asp371Asn carriers (CRC
diagnosed at 46 and 72 years of age, respectively; in-
dividuals IV-7 and III-5; Figure 1) was available to evaluate
the expression of FAF1 by immunohistochemistry and the
presence of LOH. FAF1 protein was expressed both in the
cytoplasm and the nucleus of colon tumor cells
(Supplementary Figure 1), and LOH was evident, especially
in III-5’s tumor (Supplementary Figure 3).CRISPR/Cas9 FAF1KO Modeling
To further validate the suspected role of FAF1 genetic
variants on CRC predisposition, we established an FAF1KO
cellular model by CRISPR/Cas9 gene editing on DLD-1 cells
(Figure 2). According to bioinformatic CRISPRprediction tools,
an sgRNA targeting the fourth exonwas selected because of its
favorable on-target and off-target scores. FAF1 gene editingFigure 2. CRISPR/Cas9-
mediated FAF1 gene
inactivation in the DLD-1
CRC cell line. (A) Mapping
of the identified FAF1
missense variants within
the functional domains of
the protein. (B) Overview of
the CRISPR-directed FAF1
inactivation workflow. The
20-nt sgRNA and the 3-nt
PAM sequences are
depicted. The Sanger
sequencing profile of the
edited cell pool shows an
aberrant sequence signal
after the expected break
site (red arrow). (C) FAF1
messenger RNA relative




mean ± SD (n ¼ 3). (D)
Representative Western
blot analysis of several
FAF1KO clones, confirming
FAF1 depletion on clones
#4 and #5. *P < .05, anal-
ysis of variance with Tukey
post hoc test. bp, base
pair.was checked by Sanger sequencing (Figure 2B), and FAF1
depletion was confirmed by reverse-transcriptase PCR and
Western blot (Figure 2C and D). Two FAF1KO clones (#4 and
#5) were selected for further expansion and characterization.
An initial screening of the tumor suppressor role of FAF1
was performed on CRISPR-generated knockout clones. The
functional analysis demonstrated that permanent inactiva-
tion of FAF1 resulted in a more malignant phenotype of DLD-
1 cells. Knockout clones showed a higher cell proliferation
rate on the MTS assay in comparison with FAF1WT cells
(Figure 3A), as well as a subtle increase in cell migration
(Figure 3B). Nevertheless, the most prominent effect was the
sustained resistance to programmed cell death of FAF1-
depleted cells. After exposing cells to the apoptosis-inducer
TRAIL, both caspase-3 activity and cell death were notice-
able in FAF1WT cells, whereas FAF1KO clones showed high
resistance to apoptosis (Figure 3C and Supplementary
Figure 4). FAF1 has also been described as a negative regu-
lator of the NF-kappa-B signaling pathway, as it prevents the
nuclear translocation of p65, a subunit of NF-k-B. Depletion of
FAF1 increased both the basal nuclear levels of p65 and the


















July 2020 FAF1 in Hereditary Colorectal Cancer 233as a ubiquitin-interacting protein, FAF1 has been reported to
participate in the regulation of the Wnt signaling pathway.
Lower levels of cytoplasmic beta-catenin were detected in
FAF1WT cells in comparison with FAF1KO cells, confirming
the participation of FAF1 in beta-catenin degradation
(Figure 3E). Moreover, MG132 treatment promoted the
accumulation of beta-catenin in FAF1WT cells to levels com-
parable to FAF1KO cells, indicating its participation in the
proteasomal degradation of beta-catenin. These results sup-
ported the tumor suppressor role of FAF1, which was in line
with the hypothesis that mutations affecting its correct












ATFunctional Characterization of Germline Variants
To evaluate the functional effect of the identified FAF1
variants, site-directed mutagenesis was performed on a
vector carrying the wild-type ORF of FAF1. Both c.254G>C
and c.1111G>A mutations were PCR-generated and
verified by Sanger sequencing (Figure 4A). None of them
affected FAF1 RNA or protein expression (Figure 4B and
C). In this line, a time-course expression analysis showed
that wild-type and mutated FAF1 ORFs were equally
expressed after transfection (Figure 4D), so the potential
pathogenic mechanism of these variants appeared to be
unrelated with their expression levels. Still, an amino acid
exchange is an event that can disturb the conformational
structure of a protein, thus compromising its stability and
functionality. Therefore, we performed a CETSA assay to
analyze the thermal stability of p.Arg85Pro and
p.Asp371Asn variants within the cellular environment.
The protein melting curve analysis revealed that both
substitutions had reduced FAF1 protein stability in com-
parison with its wild-type form (Figure 4E). The insta-
bility of the p.Asp371Asn variant was already noticeable
from lower point temperatures. Altogether, these results
suggest that FAF1 missense alterations might contribute
to protein dysfunction.
Because both missense variants seemed to cause protein
instability, we proceeded to functionally characterize them
by targeting the main cellular and molecular pathways in
which FAF1 participates. As FAF1 is a component of the Fas-
death-inducing signaling complex (Fas-DISC), cell resistance
to apoptosis was first analyzed by measuring caspase-3
activation. DLD-1 FAF1KO clones #4 and #5 were tran-
siently transfected with pWT, pArg85Pro, or pAsp371Asn
FAF1 vectors and exposed to TRAIL stimulation. When we
rescued the expression of wild-type FAF1, cells were sen-
sitive to TRAIL-induced apoptosis, whereas cells expressing
both p.Arg85Pro and p.Asp371Asn FAF1 variants were more=
Figure 3. FAF1 inactivation enhances a malignant phenotype.
clones cultured for 72 hours. (B) Cell migration evaluation by d
hours of wound generation. On the right, representative imag
resistance of both FAF1KO #4 and #5 clones after 16 hours of TR
#4 by Western blot analysis of nuclear lysates at basal levels (-
cytoplasmic protein lysates of FAF1WT and FAF1KO cells. When
***P < .001, analysis of variance with Tukey post hoc test. U
deviation (n ¼ 3).resistant to cell death (Figure 5A and Supplementary
Figure 5).
Another key feature of FAF1 is the regulation of NF-
kappa-B activity by preventing its nuclear translocation.
After FAF1 variant transfection, the subcellular location of
the p65 NF-kB subunit was assessed. Cells expressing either
p.Arg85Pro or p.Asp371Asn variants subtly accumulated
more p65 into the nucleus in comparison with those
expressing wild-type FAF1. A similar trend was observed for
TNFa-stimulated cells, on which the highest amount of nu-
clear p65 was detected in cells expressing the pAsp371Asn
FAF1 variant (Figure 5B). To further confirm the contribu-
tion of FAF1missense variants on NF-kappa-B activation, we
evaluated the expression of Cyclin D1 (CCND1), one of its
downstream effector genes. Again, after TNFa treatment,
FAF1 p.Asp371Asn cells exhibited a small increase in CCND1
expression in comparison with its wild-type counterpart
(Figure 5C). Next, as FAF1 negatively regulates the Wnt
signaling pathway, we tested whether FAF1 missense vari-
ants may impair the beta-catenin degradation driven by FAF1
under basal conditions. Both missense variants promoted an
increased beta-catenin accumulation in the cytoplasm, an
effect that was especially remarkable on cells expressing the
pAsp371Asn FAF1 variant (Figure 5D). Together, these re-
sults support the pro-tumorigenic consequences of FAF1
malfunction on NF-kappa-B and Wnt signaling.
To further explore the functional significance of FAF1
variants on cell malignancy, additional biological capabilities
were assessed, including cell proliferation, colony formation,
and cell migration. On transfection, cells expressing both
p.Arg85Pro and p.Asp371Asn variants showed higher pro-
liferative rate (Figure 6A) and colony formation capacity
(Figure 6B and C) in comparison with the rescued wild-type
phenotype. The proliferative effect was quite remarkable on
clone FAF1KO #4 and, at a lower rate, the same trend was
observed for clone FAF1KO #5. Regarding cell migration, the
FAF1KO #4 clone expressing p.Arg85Pro and p.Asp371Asn
FAF1 variants showed an increased wound-healing potential
in comparison with cells transfected with the wild-type
form of FAF1 (Figure 6D).Discussion
We identified 2 rare genetic variants with plausible
pathogenicity in the FAF1 gene in 2 independent cohorts of
unaffiliated familial CRC. A thorough functional character-
ization of both variants was performed in a CRISPR/Cas9
cellular model to further confirm their pathogenicity and
involvement in germline predisposition to CRC, including
assays for proliferation, colony formation, cell migration,(A) MTS cell viability assay on DLD-1 (FAF1WT) and FAF1KO
etermining the scratched area at the start point and after 24
es of the wound closure. Scale bar, 200 mm. (C) Apoptosis
AIL treatment. (D) Assessment of p65 translocation in FAF1KO
TNFa) or after TNFa-stimulation. (E) beta-catenin detection in
indicated, cells were treated with MG132. *P < .05, **P < .01,
nless otherwise indicated, data represent mean ± standard
Figure 4. Assessment of c.254G>C and c.1111G>A FAF1 variants expression and protein stability. (A) Site-directed muta-
genesis of the pcDNA3.1-FAF1-DYK vector. Sanger sequencing verification of the specific nucleotide substitutions
(c.254G>C and c.1111G>A) are depicted in red. (B) Western blot analysis and (C) real-time PCR quantification of the
expression levels of the indicated FLAG-tagged FAF1 transfected vectors at both protein and messenger RNA levels
respectively. EV, empty vector. (D) Time-course protein expression analysis on FAF1KO #4 clone revealing the pcDNA3.1
expression peak 72 hours after transfection. No remarkable expression differences were observed between FAF1 vectors a
the indicated timepoint. (E) Representative Western blot for the CETSA assay of FLAG-tagged FAF1 transfected cells, eithe
with wild-type or missense variants. On the right, band intensity quantification by densitometry. All data were normalized to the
amount of protein detected for each condition at the lowest test temperature and fitted by a 4-parameter logistic (4PL
regression. Data represent mean ± standard deviation (n ¼ 3).








Figure 5. FAF1 variants
contribute to apoptosis
resistance as well as
deregulation of NF-kappa-B
and Wnt signaling path-







(B) Western blot analysis
of p65 nuclear trans-
location at basal levels
(-TNFa) or after TNFa-
stimulation and (C) real-
time PCR quantification of
CCND1 expression levels
under the same experi-
mental conditions,
assayed in triplicate for
FAF1KO #4. (D) beta-
catenin detection in cyto-
plasmic protein lysates on
FAF1KO cells cotrans-
fected with a pcDNA3
beta-catenin expression
vector together with the
indicated FAF1 vectors.
Unless otherwise indi-
cated, data on bar graphs
represent mean ± SD (n ¼
3). *P < .05, analysis of
variance with Tukey post
hoc test.
































ATprotein stability, resistance to apoptosis, and both NF-
kappa-B and Wnt signaling.
The FAF1 genetic variant was prioritized over an RAD52
genetic variant in family FAM13 due to additional segrega-
tion in an advanced adenoma case. Human RAD52 can be
considered a nonessential gene,19 whereas FAF1 is neces-
sary for correct embryonic development.20 Accordingly,
when using the pLI score to estimate their tolerance of loss-
of-function variation,21 RAD52 pLI score is 0 as compared
with 1 for FAF1. Overall, these will be suggesting that the
latter gene will be more intolerant to mutation and more
likely to be involved in cancer predisposition.
FAF1 is an evolutionary conserved proapoptotic scaf-
folding protein. It contains 2 apoptosis-related domains (FID
and DEDID), as well as several ubiquitination-associated
functional domains. It is considered a component of the
death-inducing signaling complex (DISC), and it participates
in both receptor-dependent22 and independent23 apoptosis
pathways. Moreover, FAF1 retains the NF-kappa-B subunit
p65 in the cytoplasm via physical interaction, thus inhibiting
NF-kappa-B nuclear translocation and activation.24 In
addition, its ubiquitin-binding capacity antagonizes the ca-
nonical Wnt signaling pathway25 and participates in the
DNA replication fork dynamics.26 Therefore, FAF1 has been
contemplated as a tumor suppressor gene, whose down-
regulation may contribute to tumorigenesis. Our functional
characterization of FAF1KO clones confirmed the involve-
ment of this protein in apoptosis resistance and cell cycle
deregulation.
The identified FAF1 missense mutations in the present
study are located in well-defined functional domains. The
c.254G>C variant (p.Arg85Pro) is included in the FID
domain, whereas the c.1111G>A variant (p.Asp371Asn) is
located inside both the helix-rich DEDID and the UAS do-
mains.27 In silico pathogenicity tools predicted a possible
pathogenic conformational change of FAF1 p.Arg85Pro, as
well as a loss of acetylation of the K368 residue in FAF1
p.Asp371Asn. Acetylation usually works as a stabilizing
mechanism, preventing the ubiquitination and subsequent
proteasomal degradation of the protein.28 These results
were reinforced by the CETSA assay, which confirmed that
both amino acid substitutions altered protein stability, thus
potentially modifying protein-protein interactions.
We then assessed whether p.Arg85Pro and p.Asp371Asn
variants affected the main cellular processes in which FAF1
participates. Cells expressing p.Arg85Pro and p.Asp371Asn
FAF1 variants were more resistant to TRAIL-induced
apoptosis, which is consistent with the involvement of
both FID and DEDID domains in the death signaling cascade.
Higher NF-kappa-B activity and cytoplasmic beta-catenin
accumulation were detected mainly in p.Asp371Asn FAF1=
Figure 6. FAF1 variants also contribute to the malignant cell tra
pWT, pArg85Pro, or pAsp371Asn FAF1 variants. (A) MTS cell via
cells (ie, colonies originated from single cells) as well as (C)
Representative images of crystal violet staining of clone FAF1KO
scratched area at the start point and after 24 hours of wound
deviation (n ¼ 3). *P < .05, analysis of variance with Tukey posexpressing cells, which may be explained by the location of
this mutation inside the overlapping domains DEDID and
UAS. The DEDID domain is the one that drives the p65-FAF1
interaction and its retention into the cytoplasm.24 In the
case of beta-catenin, although the specific mechanism by
which FAF1 promotes its degradation is still unknown, it
seems to be related to its ubiquitin-binding domains.25 In
this line, Kim et al29 described that mutations disturbing the
highly conserved positive surface patch in the UAS domain
of FAF1 (352-487) conducted to beta-catenin stabilization.
Finally, the expression of both mutations increased the
proliferation rate of cells and cell survival on colony for-
mation assays. To sum up, our functional characterization
results are consistent with a pathogenic role for both
identified FAF1 missense variants.
Our findings are also in agreement with accumulating
evidence regarding the tumor suppressor profile of FAF1
and its involvement in cancer susceptibility. Single nucleo-
tide polymorphism (SNP) testing described the presence of
28 SNPs in the FAF1 genomic region that may be associated
with a high risk of gastric cancer,30 as well as 22 SNPs in the
FAF1_CDKN2C locus that may predispose to an increased
risk for papillary thyroid cancer.31 Because of its tumor
suppressor profile, loss or downregulation of somatic FAF1
could also be expected in human cancer. At the genomic
level, losses, deletions, or intragenic breakpoints at the FAF1
locus have been detected in uterine cervix carcinomas,32
glioblastoma patients,33 and mantle cell lymphoma cell
lines.34 In fact, FAF1 is located in the chromosomal region
1p32.3, recurrently lost in somatic CRC.35 Furthermore,
FAF1 downregulated expression has been frequently re-
ported in human gastric carcinomas.36,37
The balance between survival and programmed cell death
is an important homeostatic process that, when disrupted,
can facilitate the development of cancer. This equilibrium is
specially regulated in normal colonic epithelial cells at the
base of crypts, which are highly prone to apoptosis.38
Therefore, a special role can be hypothesized for those tu-
mor suppressor genes with proapoptotic functions or nega-
tively regulating both Wnt and NF-kappa-B pathways.
Accordingly, we can hypothesize that FAF1, when disrupted,
will deviate the normal homeostatic process and lead to
resistance to cell death. In this regard, several studies have
already proposed new candidate CRC predisposing genes
involved in apoptosis. The pathogenicity of a germline variant
in the proapoptotic UNC5C gene was validated and suggested
to increase the risk for CRC,39 although with controversy.40 A
screening study of a Finnish cohort identified 2 truncating
variants in the UACA gene, which was proposed as a novel
candidate gene.41 Similarities can be found between UACA
and FAF1, as both genes promote apoptosis and control thensformation. FAF1KO #4 and #5 clones were transfected with
bility assay after 72 hours of culturing. (B) Plating efficiency of
the growth capacity of cells in the colony formation assay.
#4 are shown. (D) Cell migration evaluation by determining the
generation. Data on bar graphs represent mean ± standard
t hoc test.




ATnuclear factor NF-kappa-B activity. In addition, in a previous
study from our research group, we postulated NFKBIZ as a
novel CRC candidate gene, as it interferes with the DNA
binding capacity of both p50 and p65 NF-kappa-B subunits.15
These biological processes can be relevant not only in CRC
predisposition but also in germline susceptibility to other
neoplasms. For example, germline mutations in the FAS gene,
one of the main sensors of the extrinsic apoptosis pathway,
are associated with the development of autoimmune lym-
phoproliferative syndrome and a high risk for both Hodgkin
and non-Hodgkin lymphoma.42,43
Taking into account the variants found in our series, the
FAF1 frequency in familial CRC could be considered
approximately 0.4% (2/513). When adding other genes
involved in apoptosis (UNC5C, UACA, NFKBIZ) with reported
variants in familial CRC cohorts, the frequency of apoptosis
defects could rise to >1%.39-41,44 Undoubtedly, analysis of
additional larger familial CRC cohorts is needed to provide
further information about the prevalence and implication of
mutations in FAF1 and other apoptosis-related genes in
hereditary CRC.
In summary, our findings suggest germline FAF1 muta-
tions may be implicated in inherited susceptibility to CRC,
and postulate resistance to apoptosis as the plausible un-
derlying mechanism.Supplementary Material
Note: To access the supplementary material accompanying
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Supplementary Material.
Exome Sequencing and Variant
Identification
Exome Sequencing and Variant Prioritization in
Initial Cohort
Germline DNA samples used for exome sequencing were
isolated from peripheral blood using the QIAamp DNA
Blood (Qiagen, Hilden, Germany) following the manufac-
turer’s instructions.
Whole-exome sequencing (WES) was performed in
samples of selected patients using the HiSeq2000 platform
(Illumina, San Diego, CA) and SureSelectXT Human All Exon
v5 kit (Agilent, Santa Clara, CA) for exon enrichment. WES
cannot reliably detect copy-number variants as in large
deletions/duplication/insertions. Indexed libraries were
pooled and massively parallel sequenced using a paired-
end 2  75-base pair read length protocol. Quality con-
trol of sequencing data was made in all samples previously
to their analysis using the Real-Time Analysis software
sequence pipeline (Illumina, San Diego, CA). Burrows-
Wheeler Aligner (BWA-MEM algorithm) was used for
read mapping to the human reference genome (build
hs37d5, based on NCBI GRCh37).1 PCR duplicates were
discarded using MarkDuplicates tool from Picard and then
indel realignment and base quality score recalibration were
performed with the Genome Analysis Toolkit (GATK).2
The GATK tools HaplotypeCaller and MuTect2 were
used for SNV and short indels calling for germline and
tumor samples, respectively.2 Regarding variant annota-
tion, different databases were considered, including
SnpEff, ANNOVAR, and dbNSFP, for pathogenicity and
variant position annotation. PhyloP (phyloP46way_pla-
cental score  1.6), SIFT (prediction of damaging), Poly-
Phen2 (HumVar prediction of probably damaging or
possibly damaging), MutationTaster (prediction of disease-
causing or disease-causing-automatic), LRT (prediction of
deleterious), and CADD (Phred score  15) were used for
pathogenicity prediction of missense variants. Germline
WES data were analyzed through an in-house R language
pipeline described in previous studies.3–5 Functions
related with CRC or cancer were prioritized. DNA repair,
apoptosis, autophagy, cell growth, cell proliferation, in-
flammatory response, cell cycle, angiogenesis, cell differ-
entiation, cell adhesion, and chromatin modification,
among others, were included.
Variant Identification in Pooled Samples in
Replication Cohort
Patients were screened for genetic variants in FAF1 using a
combination of PCR amplification in pooled DNAs and targeted
massively parallel sequencing, as previously described.6
Primers are listed in Supplementary Table 2. Again, variant
prioritization was performed as previously described.3–5
Variant Validation, Segregation Analysis, and
Tumor LOH
Results for the prioritized variants in initial and repli-
cation cohorts were validated by using specific primers for
PCR amplification designed using Primer3Plus7 and Sanger
sequencing (GATC Biotech, Cologne, Germany). Segregation
analysis of the prioritized variants was performed when
possible in additional family members affected with CRC or
advanced adenoma (Supplementary Figure 2). LOH was
tested by comparing Sanger sequencing results including
the identified variant from germline and tumor DNA of the
same individual. Primers are listed in Supplementary
Table 1.
Additional Pathogenicity Prediction Tools
Besides the bioinformatic pathogenicity tools used in the
variant prioritization process, 2 additional in silico tools
were used to predict protein structural alterations
(DAMpred, https://zhanglab.ccmb.med.umich.edu/
DAMpred/)8 and molecular mechanisms that could
become altered and lead to protein misfunction (MutPred2,
http://mutpred.mutdb.org/).9
Immunohistochemistry
Immunostains were performed on histological 2-mm
sections from colon tumor and normal mucosa from patient
III-5 of family FAM13. After deparaffination, antigen
retrieval was performed with citrate buffer 10 mM, and
tissue was permeabilized with 1% Triton X-100. Peroxidase
activity was blocked with 3% hydrogen peroxide. Sections
were treated for 2 hours with Dako serum-free protein
blocker (Agilent, Santa Clara, CA), incubated for 16 hours
with monoclonal rabbit anti-FAF1 antibody at 1/700 dilu-
tion (ab183045, Abcam, Cambridge, UK), and for 1 hour
with goat anti-rabbit secondary antibody at 37C (Dako
REAL EnVision HRP Rabbit; Agilent). Sections were
revealed with diaminobenzidine for 25 seconds (Agilent),
counterstained with hematoxylin, and mounted. An
Olympus BX41 microscope (Olympus, Tokyo, Japan) was
used to visualize the immunostains.




The Benchling (http://benchling.com) and the MIT
(http://crispr.mit.edu) CRISPR tools were used to design
the sgRNA against the coding region of the FAF1 gene. The
top and bottom strands of the sgRNA were purchased
from IDT (Coralville, IA) and cloned into the Lenti-
CRISPRv2-Puro vector (which also packages the Cas9
coding sequence) as follows. Briefly, LentiCRISPRv2-Puro
vector was digested with Esp3I (Thermo Fisher,
July 2020 FAF1 in Hereditary Colorectal Cancer 240.e1
Waltham, MA) and run on 0.8% agarose gel. The 12-kb
band corresponding to the plasmid backbone was
extracted with the QIAquick Gel Extraction Kit (Qiagen,
Hilden, Germany). The sgRNA-encoding oligonucleotides
were annealed, phosphorylated with the T4 Poly-
nucleotide Kinase (NEB, Ipswich, MA), and ligated into the
LentiCRISPR backbone with T4 ligase (NEB, Ipswich, MA).
The vector was transiently transfected into the DLD-1 CRC
cell line using X-tremeGENE HP DNA transfection reagent
(Roche, Basel, Switzerland), thus avoiding the stable
expression of Cas9 and reducing its subsequent undesired
effects, such as off-target activity and cytotoxicity. Two
days later, transfected cells were puromycin-selected (4
mg/mL) and CRISPR-editing efficacy on the targeted locus
was verified by Sanger sequencing and TIDE webtool
analysis.10 For single-cell cloning, puromycin-resistant
cells were seeded into a 96-well plate at a density of 1
cell/well. After 3 weeks, several clones were characterized
and selected for further analysis. FAF1 editing was vali-
dated by Sanger sequencing, and gene inactivation was
checked by quantitative real-time PCR and Western blot.
Primers are listed in Supplementary Table 3.
Protein Extraction and Western Blot
To obtain whole-cell protein extracts, cells were de-
tached from cell culture plates with Accutase (Sigma
Aldrich, St Louis, MO) and lysed with RIPA buffer supple-
mented with cOmplete Protease Inhibitor Cocktail and
PhosSTOP (Roche). To assess NF-kappa-B translocation and
beta-catenin accumulation, cytoplasmic and nuclear protein
fractions were separated as follows. Cells were resuspended
in ice-cold hypotonic buffer (Tris 10 mM, NaCl 10 mM,
MgCl2 10 mM) and lysed with 1% NP-40. Cytoplasmic
proteins were separated from nuclei by high-speed centri-
fugation, and the nuclear protein fraction was lysed by
pulse sonication and RIPA extraction. Sample protein con-
centrations were determined by using the Pierce BCA Pro-
tein Assay Kit (Thermo Fisher, Waltham, MA). Equal
amounts of protein lysates were resolved in NuPAGE Bis-
Tris protein gel electrophoresis, followed by protein trans-
fer onto Immobilion PVDF membranes (Millipore, Bedford,
MA), according to manufacturer’s protocols (Thermo
Fisher). Proteins were blotted with the indicated primary
and secondary Dylight antibodies and detected by using the
Odyssey Imaging System (LI-COR, Lincoln, NE).
RNA Extraction and Quantitative Real-Time PCR
Total RNA extraction was performed with the RNeasy
Mini Kit according to manufacturer’s instructions (Qiagen).
RNA was retrotranscribed using the Applied Biosystems
High-Capacity cDNA Reverse Transcription Kit (Thermo
Fisher). Multiplex quantitative PCR was performed with the
Applied Biosystems (Foster City, CA) 7300 PCR System by
using specific TaqMan assays for FAF1-FAM
(hs00169544_m1) and CCND1-FAM (hs00765553_m1). The
endogenous control gene was GAPDH-VIC (4326317E).
Relative expression levels of each target gene were calcu-
lated for each sample as –DCt values (–DCt¼ – [Ct target
gene – Ct endogenous control]).
Cell Proliferation
The proliferative capacity of cells was determined using
the colorimetric CellTiter 96 AQueous One Solution Cell
Proliferation Assay kit (Promega, Madison, WI). Transfected
cells were seeded at a density of 5000 cells per well in a 96-
well plate, in quintuplicate. After 72 hours, 20 mL of Cell-
Titer 96 aqueous reagent was added to each well. Plates
were incubated at 37C for 3 hours and absorbance was
read at 490 nm using an Epoch Microplate Spectropho-
tometer (BioTek, Winooski, VT).
Colony Formation Assay
Single-cell suspensions were prepared with Accutase and
by filtration through a 40 mm cell strainer when needed. A
total of 200 cells per well were seeded into a 6-well plate in
complete growth medium. After 14 days, colonies were fixed
in methanol and stained with 0.5% crystal violet (Sigma
Aldrich). Colonies were imaged on an EliSpot Reader System
(AID GmbH, Strassberg, Germany) and analyzed by ImageJ
(National Institutes of Health, Bethesda, MD).
Migration Assay
The wound-healing assay was performed by seeding
transfected cells until confluence in 12-well plates. Cells
were treated with 0.2 mg/mL of mitomycin C to arrest
proliferation before scratching the confluent cell monolayer
with a sterile pipette tip. Migration was monitored every 24
hours until scratch closure. Images were acquired by using
the Cell
ˇ
R software on an Olympus IX51 microscope (Tokyo,
Japan). ImageJ software was used to quantify the scratch
closure area at each time point.
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Supplementary Figure 1. Immunohistochemistry analysis. FAF1 immunohistochemical staining in normal colonic mucosa of a
control individual and tumor tissue of a FAF1 c.111G>A mutation carrier (FAM13, individual III-5). A general FAF1 intracellular
staining is detected.
Supplementary Figure 2. Variant validation and segregation analysis. (A) c.1111G>A (p.Asp371Asn) FAF1 variant in FAM13.
Sequencing results show the heterozygous change in individuals III-3, III-5, IV-5, and IV-7. Sequencing results are shown using
the reverse primer. The observed C>T heterozygous change corresponds to G>A in the forward orientation. (B) c.254G>C
(p.Arg85Pro) FAF1 variant in F-0681-00. Sequencing results show the G>C heterozygous change in the patient’s sample. A
reference sequence from a noncarrier is also presented.
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Supplementary Figure 3. LOH results.
LOH tested for 2 c.1111G>A
(p.Asp371Asn) FAF1 variant carriers
(FAM13, individuals IV-7 and III-5). Re-
sults show a slight LOH in the tumor
from patient IV-7 and a complete
depletion of the wild-type allele in the
case of the patient III-5.
Supplementary Figure 4. CRISPR/Cas9 FAF1KO modeling results. Time-course development of TRAIL-induced apoptosis,
measured as caspase-3 activation (n ¼ 1). On the right, representative images of treated cells at the indicated timepoints.
Scale bar, 200 mm.
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Supplementary Figure 5. Functional characterization of
germline variants results. Determination of caspase-3 activity
after TRAIL-induced apoptosis on FAF1KO 5. Cells expressing
both p.Arg85Pro and p.Asp371Asn FAF1 variants were more
resistant to cell death in comparison to those expressing the
wild-type form of FAF1.
Supplementary Table 1.PCR primers used in the study
Forward Reverse
FAF1 c.1111G>A TCTTAGAATTTGATAGGCCAAAA TTCTATTGCTGGACCCAAAG
FAF1 c.254G>C GAAGAACAACACAAGCCAAGT CCCTTCTTGCACTGGTAGTC
NOTE. Sanger validation of FAF1 missense variants on patients’ samples.
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Supplementary Table 3.CRISPR Gene Editing
Forward Reverse
FAF1 sgRNA CACCGTTCGACCTGTAATGCCATCC aaacGGATGGCATTACAGGTCGAAC
lentiCRISPR sgRNA cloning verification GAGGGCCTATTTCCCATGATT CCACTCCTTTCAAGACCTAGC
FAF1 gene editing verification ATGGAGGTGAGACCATACCA TGGCAGGAAAAACCTTACCA
Supplementary Table 4.Site-Directed Mutagenesis
Forward Reverse
FAF1 ORF c.1111G>A mutagenesis GAAAGCCCGAaATAGAAAGCTTC ACATAGAAGGCCTCTTGAAAAG
FAF1 ORF c.1111G>A sequencing GGTGATTGCCATCCTGTATTT TTGCTCTGTTGGAGTCCTTT
FAF1 ORF c.254G>C mutagenesis TCAGCGTTTCcACCTGTAATG AGAAGAAGAGGAAGTAGG
FAF1 ORF c.254G>C sequencing ATGGAGGTGAGACCATACCA CCAACAGTACAGGTGTCTTCAA
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